A Phase 1/2 interventional study of Relatlimab and Nivolumab in Neoplasms by Site, sponsored by Bristol-Myers Squibb. Completed at 54 sites in 15 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-04-06.
Sponsored by Bristol-Myers Squibb · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 119 studies in Neoplasms by Site with a site in United States — 31 open to participants now, 44 under way, 7 of them phase 3. Neoplasms by Site · United States.
Among the 119 studies in Neoplasms by Site with a site in United States, this one is the 3rd largest by enrollment of the 102 interventional ones that give a count, is one of 3 that started in 2013, is one of 23 in phase 1/2, and was the 29th registered.
208 studies on the registry are indexed under Neoplasms by Site; 53 are open to participants now.
Browse Neoplasms by Site studies →31 of the 119 studies in Neoplasms by Site with a site in United States are open now. Recruiting first, the newest first:
AstraZeneca · Sites in United States, France, Germany and 6 more countries
Ages 18–130
Astellas Pharma Global Development, Inc. · Sites in United States, Canada, Korea, Republic of and 1 more country
Ages 18+
Pfizer · Sites in United States, Argentina, Australia and 14 more countries
Ages 18+
Orca Biosystems, Inc. · Sites in United States
Ages 18+
K36 Therapeutics, Inc. · Sites in United States
Ages 18+ · Men only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 51 Neoplasms by Site studies recruiting now, 40 (78%) set no upper age limit and 6 (12%) stop at 75 or younger; 7 take children under 18; 3 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
119 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 51 · Phase 2 41 · Phase 3 21 · Phase 4 3
First in 2003; this study’s year is marked. 3 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,482 is above the median of 88 across 171 interventional studies indexed under Neoplasms by Site.
Median enrollment 102 across the 102 interventional studies, 440 across the 17 observational. Of the 70 that completed or were terminated, 40 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
88 of 119 have an industry lead sponsor. The 10 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
Bristol-Myers Squibb has 5 studies filed under Neoplasms by Site — fewer than ten, so there is no comparison to draw.
17 of the studies in Neoplasms by Site with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06119581Phase 3Eli Lilly and CompanyA Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer | 2027-11 |
| NCT05664243In8bio Inc.A Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide in Subjects With Recurrent or Newly Diagnosed Glioblastoma | 2026-12 |
| NCT05386108Stemline Therapeutics, Inc.Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer | 2026-12 |
| NCT06463665Genelux CorporationEfficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer | 2027-02 |
| NCT05462717Revolution Medicines, Inc.Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors | 2027-03-31 |
Add all 17 to your calendar (.ics) → With an account.
Among the 119 studies in Neoplasms by Site with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to assess the safety, tolerability and effectiveness of experimental medication BMS-986016 administered alone and in combination with nivolumab in patients with solid tumors that have spread and/or cannot be removed by surgery.
The following tumor types are included in this study:
Non-Small Cell Lung Cancer (NSCLC), gastric cancer, hepatocellular carcinoma, renal cell carcinoma, bladder cancer, squamous cell carcinoma of the head and neck, and melanoma, that have NOT previously been treated with immunotherapy. NSCLC and melanoma that HAVE previously been treated with immunotherapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol defined inclusion/exclusion criteria could apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relatlimab (BMS-986016) specified dose on specified days
Biological: Relatlimab
Relatlimab (BMS-986016) + Nivolumab (BMS-936558) specified dose on specified days
Biological: Relatlimab · Biological: Nivolumab
Relatlimab (BMS-986016) + Nivolumab (BMS-936558)
Biological: BMS-986213
Also known as: BMS-986016, Anti-LAG-3 (Anti-Lymphocyte Activation Gene-3)
Also known as: Anti-PD-1 (Anti-Programmed-Death-1), BMS-936558
Relatlimab + Nivolumab
Number of Participants With Adverse Events, Deaths and Clinically Relevant Laboratory Abnormalities
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. SAEs is any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires inpatient hospitalization; results significant disability; or is a congenital anomaly/birth defect.
Time frame: From first dose and within 135 days after last dose of study therapy (Up to approximately 82 months)
Part C, D1, D2, E - Objective Response Rate Per BICR
ORR is defined as the percentage of participants whose best overall response (BOR) is either CR or PR by blinded independent central review (BICR) per response evaluation criteria in solid tumors (RECIST) v1.1 based on Clopper-Pearson method. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\\< 10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum during the study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
Time frame: From first dose to the date of first objectively documented progression, per RECIST v1.1, or death due to any cause, whichever occurred first (up to approximately 127 months)
Part C, D1, D2, E - Disease Control Rate (DCR) Per BICR
Disease Control Rate (DCR) (as per Recists v1.1) is defined as the percentage of randomized participants who achieve a BOR of confirmed CR, confirmed PR, or stable disease (SD), based on BICR assessments divided by the number of all randomized participants. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\\< 10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum during the study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
Time frame: From first dose to the date of first objectively documented progression, per RECIST v1.1, or death due to any cause, whichever occurred first (up to approximately 127 months)
Part C, D1, D2, E - Duration of Response (DOR) Per BICR
DOR for a participant with a best overall response (BOR) of CR or PR is defined as the time between the date of first response and the date of the first objectively documented tumor progression by blinded independent central review (BICR) per response evaluation criteria in solid tumors (RECIST) v1.1 or death, whichever occurs first. Median computed using Kaplan-Meier method. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\\< 10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum during the study (this includes the baseline sum). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
Time frame: From first dose to the date of first objectively documented progression, per RECIST v1.1, or death due to any cause, whichever occurred first (up to approximately 127 months)
Part D1: Number of Participants With Adverse Events in the Broad Scope Standardized MedDRA (SMQ) Anaphylactic Reaction Occurring Within 2 Days of Any Doses of Study Therapy
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment.
Time frame: From first dose and within 2 days of first dose of study therapy
Part C, D1, D2, E - Objective Response Rate Per BICR
ORR is defined as the percentage of participants whose best overall response (BOR) is either CR or PR by blinded independent central review (BICR) per response evaluation criteria in solid tumors (RECIST) v1.1 based on Clopper-Pearson method. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\\< 10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum during the study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
Time frame: From first dose (Day 1) and up to 97 months
Part C, D1 and D2: Progression-Free Survival (PFS) Rate Per BICR
Progression Free Survival Rates at 12 months is defined as the proportion of participants who achieve PFS at 12 months. PFS for a participant is defined as the time from randomization date to the date of first objectively documented disease progression by blinded independent central review (BICR) per response evaluation criteria in solid tumors (RECIST) v1.1 or death due to any cause, whichever occurs first. Based on Kaplan-Meier Estimates. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum during the study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
Time frame: Up to 12 months
Part D1 and D2: Overall Survival (OS) at 12 and 24 Months
Overall survival at 1 year, and 2 years is defined as the proportion of participants who are alive at 1 year, and 2 years. Based on Kaplan-Meier Estimates.
Time frame: At 12 and 24 months after first dose
Part C, D1, D2, E - Objective Response Rate Per Investigator
ORR is defined as the percentage of participants whose best overall response (BOR) is either CR or PR by investigator per response evaluation criteria in solid tumors (RECIST) v1.1 based on Clopper-Pearson method. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\\< 10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum during the study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
Time frame: From first dose to the date of first objectively documented progression, per RECIST v1.1, or death due to any cause, whichever occurred first (up to approximately 127 months)
Part C, D1, D2, E - Disease Control Rate (DCR) Per Investigator
Disease Control Rate (DCR) (as per Recists v1.1) is defined as the percentage of randomized participants who achieve a BOR of confirmed CR, confirmed PR, or stable disease (SD), based on BICR assessments divided by the number of all randomized participants. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\\< 10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum during the study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
Time frame: From first dose to the date of first objectively documented progression, per RECIST v1.1, or death due to any cause, whichever occurred first (up to approximately 127 months)
Part C, D1, D2, E - Duration of Response (DOR) Per Investigator
DOR for a participant with a best overall response (BOR) of CR or PR is defined as the time between the date of first response and the date of the first objectively documented tumor progression by investigator per response evaluation criteria in solid tumors (RECIST) v1.1 or death, whichever occurs first. Median computed using Kaplan-Meier method. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\\< 10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum during the study (this includes the baseline sum). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
Time frame: From first dose to the date of first objectively documented progression, per RECIST v1.1, or death due to any cause, whichever occurred first (up to approximately 127 months)
Part C, D1 and D2: Progression-Free Survival (PFS) Rate Per Investigator
Progression Free Survival Rates up to 12 months is defined as the proportion of participants who achieve PFS up to 12 months. PFS for a participant is defined as the time from randomization date to the date of first objectively documented disease progression by investigator per response evaluation criteria in solid tumors (RECIST) v1.1 or death due to any cause, whichever occurs first. Based on Kaplan-Meier Estimates. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum during the study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
Time frame: Up to 12 months
Number of Participants With Positive Anti Drug Antibodies
Blood samples were collected to assess anti-drug antibodies.
Time frame: predose, and 4-hour post-dose of relatlimab on Cycle 1 Day 1 and Cycle 3 Day 1 (Each cycle consist of 28 days)
Part A, A/A1, and B: Number of Participants With Clinically Relevant QT Prolongation
Abnormal electrocardiogram parameter included QT prolongation.
Time frame: predose, and 4-hour post-dose of relatlimab on Cycle 1 Day 1 and Cycle 3 Day 1 (Each cycle consist of 28 days)
Maximum Observed Concentration (Cmax) of BMS-986016 (Relatlimab)
Blood samples were collected for assessment of pharmacokinetic parameter of BMS-986016 (relatlimab).
Time frame: Day 1 of Cycle 1 and 3
Time to Maximum Observed Concentration (Tmax) of BMS-986016 (Relatlimab)
Blood samples were collected for assessment of pharmacokinetic parameter of BMS-986016 (relatlimab).
Time frame: Day 1 of Cycle 1 and 3 (Each cycle consist of 28 days).
Area Under the Concentration-time Curve in One Dosing Interval (AUCtau) of BMS-986016 (Relatlimab)
Blood samples were collected for assessment of pharmacokinetic parameter of BMS-986016 (relatlimab).
Time frame: Day 1 of Cycle 1 and 3 (Each cycle consist of 28 days).
Part A/A1, B, C, D1, D2 and E: Trough Observed Concentration (Ctrough) of BMS-986016 (Relatlimab)
Blood samples were collected for assessment of pharmacokinetic parameter of BMS-986016 (relatlimab). Ctrough is defined as the lowest concentration of drug in the blood immediately before the next dose is administered. Ctrough was only assessed for arm Part A/A1, B, C, D1, D2 and E as pre-specified.
Time frame: Day 1 of Cycle 3 (Each cycle consist of 28 days)
Part A/A1, B, CTotal Body Clearance (CLT) of BMS-986016 (Relatlimab)
Blood samples were collected for assessment of pharmacokinetic parameter of BMS-986016 (relatlimab). CLT was only assessed for arm Part A/A1, B, C as pre-specified.
Time frame: Day 1 of Cycle 3 (Each cycle consist of 28 days).
Part A/A1, B, C AUC Accumulation Index AI_AUC of BMS-986016 (Relatlimab)
Blood samples were collected for assessment of pharmacokinetic parameter of BMS-986016 (relatlimab). AUC Accumulation Index is a pharmacokinetic metric used to quantify how much a drug accumulates in the body after repeated dosing compared to a single dose. It is ratio of AUC Steady State (AUCss) and AUC1. AUCₛₛ is the area under the plasma concentration-time curve during a dosing interval at steady state (after repeated doses). AUC₁ is the area under the curve after a single dose. Only assessed for arm Part A/A1, B, C as pre-specified.
Time frame: Day 1 of Cycle 3 (Each cycle consist of 28 days)
| Milestone | BMS-986016 (Relatlimab) Monotherapy 20 Milligram (mg) (Part A) | BMS-986016 (Relatlimab) Monotherapy 80 Milligram (mg) (Part A) | BMS-986016 (Relatlimab) Monotherapy 240 Milligram (mg) (Part A) | BMS-986016 (Relatlimab) Monotherapy 800 Milligram (mg) (Part A/A1) | Combination-Escalation-BMS-986016 (Relatlimab)/Nivolumab (20 mg/80 mg) (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (20 mg/240 mg (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (80 mg/240 mg) (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (160 mg/240 mg) (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (240 mg/240 mg) (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (160 mg/480 mg) (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (240 mg/480 mg) (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (320 mg/480 mg) (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (480 mg/480 mg) (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (960 mg/480 mg) (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (1440 mg/480 mg) (Part B) | NSCLC IO Naive-80/240 (Part C) | MEL 1L-80/240 (Part C) | RCC IO Naive-80/240 (Part C) | SCCHN IO Naive-80/240 (Part C) | HCC IO Naive-80/240 (Part C) | Gastric IO Naive-80/240 (Part C) | Bladder IO Naive-160/480 (Part C) | NSCLC Prior IO-80/240 (Part C) | MEL Prior IO - 80/240 (Part C) | MEL Prior IO Rf-80/240 Q2W (Part D1 Coad) | MEL Prior IO Rf-160/480 Q4W (Part D1 Coad) | MEL Prior IO Rf-160/480 (Part D1 FDC) | MEL Prior IO Rf-160/480 (Part D2) | MEL 1L-160/480 (Part E) | MEL 1L-480/480 (Part E) | MEL Prior IO rf - 480/480 (Part E) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 5 | 4 | 4 | 12 | 7 | 9 | 8 | 8 | 8 | 8 | 8 | 8 | 7 | 17 | 19 | 24 | 66 | 26 | 65 | 63 | 94 | 37 | 57 | 151 | 189 | 83 | 82 | 164 | 77 | 77 | 95 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 5 | 4 | 4 | 12 | 7 | 9 | 8 | 8 | 8 | 8 | 8 | 8 | 7 | 17 | 19 | 24 | 66 | 26 | 65 | 63 | 94 | 37 | 57 | 151 | 189 | 83 | 82 | 164 | 77 | 77 | 95 |
| Withdrew: Disease progression | 4 | 4 | 3 | 9 | 5 | 6 | 6 | 6 | 4 | 5 | 8 | 4 | 7 | 14 | 14 | 13 | 34 | 20 | 54 | 46 | 77 | 25 | 47 | 125 | 154 | 63 | 66 | 137 | 35 | 23 | 71 |
| Withdrew: Subject request to discontinue study treatment | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 3 | 0 | 3 | 4 | 7 | 3 | 2 | 3 | 8 | 12 | 3 |
| Withdrew: Study drug toxicity | 0 | 0 | 1 | 2 | 1 | 1 | 1 | 0 | 2 | 1 | 0 | 2 | 0 | 2 | 2 | 4 | 11 | 3 | 4 | 9 | 6 | 4 | 3 | 8 | 9 | 8 | 3 | 9 | 15 | 21 | 9 |
| Withdrew: Subject withdrew consent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 0 | 3 | 2 | 1 | 4 | 0 | 1 | 1 |
| Withdrew: Adverse event unrelated to study drug | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 0 | 1 | 0 | 1 | 0 | 2 | 4 | 0 | 4 | 3 | 2 | 3 | 4 | 1 | 5 | 6 | 2 | 2 | 3 | 4 | 3 |
| Withdrew: Completed treatment as per protocol | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 10 | 1 | 1 | 1 | 2 | 1 | 0 | 10 | 5 | 0 | 1 | 2 | 0 | 0 | 1 |
| Withdrew: Other reasons | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 3 | 1 | 1 | 0 | 0 | 1 | 1 | 2 | 0 | 0 | 5 | 1 | 5 | 5 | 11 | 10 | 4 |
| Withdrew: Maximum clinical benefit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 1 | 0 | 2 | 1 | 0 | 0 | 0 | 1 | 0 | 2 | 2 | 5 | 6 | 2 |
| Withdrew: Subject no longer meets study criteria | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. SAEs is any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires inpatient hospitalization; results significant disability; or is a congenital anomaly/birth defect.
| Participants | BMS-986016 (Relatlimab) Monotherapy 20 Milligram (mg) (Part A) | BMS-986016 (Relatlimab) Monotherapy 80 Milligram (mg) (Part A) | BMS-986016 (Relatlimab) Monotherapy 240 Milligram (mg) (Part A) | BMS-986016 (Relatlimab) Monotherapy 800 Milligram (mg) (Part A/A1) | Combination-Escalation-BMS-986016 (Relatlimab)/Nivolumab (20 mg/80 mg) (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (20 mg/240 mg (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (80 mg/240 mg) (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (160 mg/240 mg) (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (240 mg/240 mg) (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (160 mg/480 mg) (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (240 mg/480 mg) (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (320 mg/480 mg) (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (480 mg/480 mg) (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (960 mg/480 mg) (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (1440 mg/480 mg) (Part B) | NSCLC IO Naive-80/240 (Part C) | MEL 1L-80/240 (Part C) | RCC IO Naive-80/240 (Part C) | SCCHN IO Naive-80/240 (Part C) | HCC IO Naive-80/240 (Part C) | Gastric IO Naive-80/240 (Part C) | Bladder IO Naive-160/480 (Part C) | NSCLC Prior IO-80/240 (Part C) | MEL Prior IO - 80/240 (Part C) | MEL Prior IO Rf-80/240 Q2W (Part D1 Coad) | MEL Prior IO Rf-160/480 Q4W (Part D1 Coad) | MEL Prior IO Rf-160/480 (Part D1 FDC) | MEL Prior IO Rf-160/480 (Part D2) | MEL 1L-160/480 (Part E) | MEL 1L-480/480 (Part E) | MEL Prior IO rf - 480/480 (Part E) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Adverse Events | 5 | 4 | 4 | 12 | 7 | 9 | 8 | 8 | 8 | 7 | 8 | 8 | 7 | 17 | 19 | 23 | 62 | 26 | 64 | 63 | 94 | 35 | 57 | 140 | 186 | 81 | 80 | 161 | 76 | 77 | 93 |
| Serious Adverse Events | 5 | 3 | 3 | 7 | 5 | 7 | 6 | 6 | 7 | 5 | 5 | 6 | 3 | 10 | 12 | 15 | 38 | 17 | 44 | 49 | 69 | 28 | 36 | 98 | 118 | 58 | 49 | 113 | 49 | 47 | 70 |
| AEs leading to discontinuation | 1 | 0 | 2 | 3 | 1 | 3 | 2 | 0 | 3 | 2 | 0 | 3 | 0 | 4 | 3 | 6 | 14 | 9 | 19 | 20 | 18 | 10 | 15 | 32 | 23 | 18 | 10 | 23 | 19 | 27 | 14 |
| Deaths | 5 | 3 | 4 | 11 | 5 | 7 | 6 | 7 | 6 | 8 | 6 | 6 | 4 | 16 | 13 | 17 | 37 | 17 | 57 | 49 | 80 | 29 | 54 | 116 | 155 | 71 | 64 | 135 | 27 | 32 | 82 |
| Clinically Relevant Laboratory Abnormalities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Death due to Disease | 5 | 3 | 3 | 11 | 5 | 7 | 6 | 6 | 5 | 8 | 5 | 3 | 4 | 14 | 12 | 14 | 32 | 17 | 48 | 43 | 74 | 29 | 48 | 112 | 138 | 67 | 59 | 127 | 24 | 27 | 73 |
| Death due to unknown reason | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 2 | 0 | 2 | 0 | 0 | 3 | 0 | 1 | 6 | 3 | 0 | 2 | 3 | 12 | 1 | 2 | 3 | 1 | 3 | 1 |
| Death due to study drug toxicity | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Death due to other reasons | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 3 | 2 | 0 | 6 | 0 | 3 | 0 | 3 | 1 | 5 | 3 | 3 | 5 | 2 | 1 | 2 |
ORR is defined as the percentage of participants whose best overall response (BOR) is either CR or PR by blinded independent central review (BICR) per response evaluation criteria in solid tumors (RECIST) v1.1 based on Clopper-Pearson method. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\\< 10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum during the study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
| percentage of participants | NSCLC IO Naive-80/240 (Part C) | MEL 1L-80/240 (Part C) | RCC IO Naive-80/240 (Part C) | SCCHN IO Naive-80/240 (Part C) | HCC IO Naive-80/240 (Part C) | Gastric IO Naive-80/240 (Part C) | Bladder IO Naive-160/480 (Part C) | NSCLC Prior IO-80/240 (Part C) | MEL Prior IO - 80/240 (Part C) | MEL Prior IO Rf-80/240 Q2W (Part D1 Coad) | MEL Prior IO Rf-160/480 Q4W (Part D1 Coad) | MEL Prior IO Rf-160/480 (Part D1 FDC) | MEL Prior IO Rf-160/480 (Part D2) | MEL 1L-160/480 (Part E) | MEL 1L-480/480 (Part E) | MEL Prior IO rf - 480/480 (Part E) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Part C, D1, D2, E - Objective Response Rate Per BICR | 29.2 (12.6 to 51.1) | 47.0 (34.6 to 59.7) | 15.4 (4.4 to 34.9) | 15.4 (7.6 to 26.5) | 15.9 (7.9 to 27.3) | 8.6 (3.8 to 16.2) | 30.6 (16.3 to 48.1) | 5.3 (1.1 to 14.6) | 10.7 (6.2 to 16.7) | 12.4 (8.0 to 18.0) | 7.2 (2.7 to 15.1) | 19.5 (11.6 to 29.7) | 9.1 (5.2 to 14.6) | 48.7 (37.0 to 60.4) | 61.0 (49.2 to 72.0) | 10.6 (5.2 to 18.7) |
Disease Control Rate (DCR) (as per Recists v1.1) is defined as the percentage of randomized participants who achieve a BOR of confirmed CR, confirmed PR, or stable disease (SD), based on BICR assessments divided by the number of all randomized participants. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\\< 10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum during the study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
| percentage of participants | NSCLC IO Naive-80/240 (Part C) | MEL 1L-80/240 (Part C) | RCC IO Naive-80/240 (Part C) | SCCHN IO Naive-80/240 (Part C) | HCC IO Naive-80/240 (Part C) | Gastric IO Naive-80/240 (Part C) | Bladder IO Naive-160/480 (Part C) | NSCLC Prior IO-80/240 (Part C) | MEL Prior IO - 80/240 (Part C) | MEL Prior IO Rf-80/240 Q2W (Part D1 Coad) | MEL Prior IO Rf-160/480 Q4W (Part D1 Coad) | MEL Prior IO Rf-160/480 (Part D1 FDC) | MEL Prior IO Rf-160/480 (Part D2) | MEL 1L-160/480 (Part E) | MEL 1L-480/480 (Part E) | MEL Prior IO rf - 480/480 (Part E) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Part C, D1, D2, E - Disease Control Rate (DCR) Per BICR | 50.0 (29.1 to 70.9) | 59.1 (46.3 to 71.0) | 46.2 (26.6 to 66.6) | 49.2 (36.6 to 61.9) | 50.8 (37.9 to 63.6) | 25.8 (17.3 to 35.9) | 44.4 (27.9 to 61.9) | 40.4 (27.6 to 54.2) | 38.0 (30.2 to 46.3) | 39.2 (32.2 to 46.7) | 32.5 (22.6 to 43.7) | 50.0 (38.7 to 61.3) | 37.8 (30.4 to 45.7) | 61.8 (50.0 to 72.8) | 68.8 (57.3 to 78.9) | 39.4 (29.4 to 50.0) |
DOR for a participant with a best overall response (BOR) of CR or PR is defined as the time between the date of first response and the date of the first objectively documented tumor progression by blinded independent central review (BICR) per response evaluation criteria in solid tumors (RECIST) v1.1 or death, whichever occurs first. Median computed using Kaplan-Meier method. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\\< 10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum during the study (this includes the baseline sum). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
| months | NSCLC IO Naive-80/240 (Part C) | MEL 1L-80/240 (Part C) | RCC IO Naive-80/240 (Part C) | SCCHN IO Naive-80/240 (Part C) | HCC IO Naive-80/240 (Part C) | Gastric IO Naive-80/240 (Part C) | Bladder IO Naive-160/480 (Part C) | NSCLC Prior IO-80/240 (Part C) | MEL Prior IO - 80/240 (Part C) | MEL Prior IO Rf-80/240 Q2W (Part D1 Coad) | MEL Prior IO Rf-160/480 Q4W (Part D1 Coad) | MEL Prior IO Rf-160/480 (Part D1 FDC) | MEL Prior IO Rf-160/480 (Part D2) | MEL 1L-160/480 (Part E) | MEL 1L-480/480 (Part E) | MEL Prior IO rf - 480/480 (Part E) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Part C, D1, D2, E - Duration of Response (DOR) Per BICR | 40.4 (6.4 to 51.4) | NA (1.9 to 65.6) | NA (3.0 to 58.2) | 27.9 (3.7 to 28.6) | 54.6 (11.7 to 75.5) | 35.1 (6.8 to 62.1) | 18.7 (5.6 to 57.9) | 8.6 (5.6 to 9.9) | 21.1 (3.2 to 57.5) | 24.5 (3.6 to 66.5) | 29.4 (12.6 to 38.8) | 20.7 (5.5 to 59.1) | 12.8 (1.3 to 55.0) | NA (5.6 to 53.2) | NA (6.5 to 49.9) | NA (2.0 to 51.8) |
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment.
| Participants | MEL Prior IO Rf-80/240 Q2W (Part D1 Coad) | MEL Prior IO Rf-160/480 Q4W (Part D1 Coad) | MEL Prior IO Rf-160/480 (Part D1 FDC) |
|---|---|---|---|
| Pruritus | 14 | 2 | 2 |
| Rash | 11 | 3 | 4 |
| Erythema | 2 | 3 | 1 |
| Rash erythematous | 1 | 0 | 1 |
| Rash pruritic | 1 | 0 | 0 |
| Urticaria | 1 | 0 | 1 |
| Cough | 8 | 3 | 4 |
| Dyspnea | 6 | 2 | 2 |
| Wheezing | 1 | 0 | 0 |
| Hypotension | 2 | 2 | 1 |
| Flushing | 1 | 0 | 0 |
ORR is defined as the percentage of participants whose best overall response (BOR) is either CR or PR by blinded independent central review (BICR) per response evaluation criteria in solid tumors (RECIST) v1.1 based on Clopper-Pearson method. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\\< 10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum during the study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
| percentage of participants | NSCLC IO Naive-80/240 (Part C) | MEL 1L-80/240 (Part C) | RCC IO Naive-80/240 (Part C) | SCCHN IO Naive-80/240 (Part C) | HCC IO Naive-80/240 (Part C) | Gastric IO Naive-80/240 (Part C) | Bladder IO Naive-160/480 (Part C) | NSCLC Prior IO-80/240 (Part C) | MEL Prior IO - 80/240 (Part C) | MEL Prior IO Rf-80/240 Q2W (Part D1 Coad) | MEL Prior IO Rf-160/480 Q4W (Part D1 Coad) | MEL Prior IO Rf-160/480 (Part D1 FDC) | MEL Prior IO Rf-160/480 (Part D2) | MEL 1L-160/480 (Part E) | MEL 1L-480/480 (Part E) | MEL Prior IO rf - 480/480 (Part E) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Part C, D1, D2, E - Objective Response Rate Per BICR | 29.2 (12.6 to 51.1) | 47.0 (34.6 to 59.7) | 15.4 (4.4 to 34.9) | 15.4 (7.6 to 26.5) | 15.9 (7.9 to 27.3) | 8.6 (3.8 to 16.2) | 30.6 (16.3 to 48.1) | 5.3 (1.1 to 14.6) | 10.7 (6.2 to 16.7) | 12.4 (8.0 to 18.0) | 7.2 (2.7 to 15.1) | 19.5 (11.6 to 29.7) | 9.1 (5.2 to 14.6) | 48.7 (37.0 to 60.4) | 61.0 (49.2 to 72.0) | 10.6 (5.2 to 18.7) |
Progression Free Survival Rates at 12 months is defined as the proportion of participants who achieve PFS at 12 months. PFS for a participant is defined as the time from randomization date to the date of first objectively documented disease progression by blinded independent central review (BICR) per response evaluation criteria in solid tumors (RECIST) v1.1 or death due to any cause, whichever occurs first. Based on Kaplan-Meier Estimates. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum during the study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
| proportion of participants | NSCLC IO Naive-80/240 (Part C) | MEL 1L-80/240 (Part C) | RCC IO Naive-80/240 (Part C) | SCCHN IO Naive-80/240 (Part C) | HCC IO Naive-80/240 (Part C) | Gastric IO Naive-80/240 (Part C) | Bladder IO Naive-160/480 (Part C) | NSCLC Prior IO-80/240 (Part C) | MEL Prior IO - 80/240 (Part C) | MEL Prior IO Rf-80/240 Q2W (Part D1 Coad) | MEL Prior IO Rf-160/480 Q4W (Part D1 Coad) | MEL Prior IO Rf-160/480 (Part D1 FDC) | MEL Prior IO Rf-160/480 (Part D2) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Part C, D1 and D2: Progression-Free Survival (PFS) Rate Per BICR | 0.28 (0.11 to 0.47) | 0.48 (0.35 to 0.60) | 0.29 (0.12 to 0.48) | 0.17 (0.08 to 0.27) | 0.24 (0.14 to 0.36) | 0.09 (0.04 to 0.16) | 0.25 (0.12 to 0.41) | 0.11 (0.04 to 0.21) | 0.13 (0.08 to 0.20) | 0.22 (0.16 to 0.29) | 0.18 (0.11 to 0.28) | 0.29 (0.20 to 0.40) | 0.16 (0.10 to 0.23) |
Overall survival at 1 year, and 2 years is defined as the proportion of participants who are alive at 1 year, and 2 years. Based on Kaplan-Meier Estimates.
| proportion of participants | MEL Prior IO Rf-80/240 Q2W (Part D1 Coad) | MEL Prior IO Rf-160/480 Q4W (Part D1 Coad) | MEL Prior IO Rf-160/480 (Part D1 FDC) | MEL Prior IO Rf-160/480 (Part D2) |
|---|---|---|---|---|
| 12 months | 0.56 (0.49 to 0.63) | 0.51 (0.39 to 0.61) | 0.57 (0.46 to 0.67) | 0.59 (0.52 to 0.67) |
| 24 months | 0.30 (0.24 to 0.37) | 0.31 (0.21 to 0.41) | 0.37 (0.27 to 0.48) | 0.38 (0.31 to 0.45) |
ORR is defined as the percentage of participants whose best overall response (BOR) is either CR or PR by investigator per response evaluation criteria in solid tumors (RECIST) v1.1 based on Clopper-Pearson method. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\\< 10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum during the study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
| percentage of participants | NSCLC IO Naive-80/240 (Part C) | MEL 1L-80/240 (Part C) | RCC IO Naive-80/240 (Part C) | SCCHN IO Naive-80/240 (Part C) | HCC IO Naive-80/240 (Part C) | Gastric IO Naive-80/240 (Part C) | Bladder IO Naive-160/480 (Part C) | NSCLC Prior IO-80/240 (Part C) | MEL Prior IO - 80/240 (Part C) | MEL Prior IO Rf-80/240 Q2W (Part D1 Coad) | MEL Prior IO Rf-160/480 Q4W (Part D1 Coad) | MEL Prior IO Rf-160/480 (Part D1 FDC) | MEL Prior IO Rf-160/480 (Part D2) | MEL 1L-160/480 (Part E) | MEL 1L-480/480 (Part E) | MEL Prior IO rf - 480/480 (Part E) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Part C, D1, D2, E - Objective Response Rate Per Investigator | 41.7 (22.1 to 63.4) | 50.0 (37.4 to 62.6) | 11.5 (2.4 to 30.2) | 15.4 (7.6 to 26.5) | 15.9 (7.9 to 27.3) | 15.1 (8.5 to 24.0) | 36.1 (20.8 to 53.8) | 5.3 (1.1 to 14.6) | 8.7 (4.7 to 14.4) | 12.9 (8.4 to 18.6) | 8.4 (3.5 to 16.6) | 17.1 (9.7 to 27.0) | 9.1 (5.2 to 14.6) | 46.1 (34.5 to 57.9) | 61.0 (49.2 to 72.0) | 16.0 (9.2 to 25.0) |
Disease Control Rate (DCR) (as per Recists v1.1) is defined as the percentage of randomized participants who achieve a BOR of confirmed CR, confirmed PR, or stable disease (SD), based on BICR assessments divided by the number of all randomized participants. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\\< 10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum during the study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
| percentage of participants | NSCLC IO Naive-80/240 (Part C) | MEL 1L-80/240 (Part C) | RCC IO Naive-80/240 (Part C) | SCCHN IO Naive-80/240 (Part C) | HCC IO Naive-80/240 (Part C) | Gastric IO Naive-80/240 (Part C) | Bladder IO Naive-160/480 (Part C) | NSCLC Prior IO-80/240 (Part C) | MEL Prior IO - 80/240 (Part C) | MEL Prior IO Rf-80/240 Q2W (Part D1 Coad) | MEL Prior IO Rf-160/480 Q4W (Part D1 Coad) | MEL Prior IO Rf-160/480 (Part D1 FDC) | MEL Prior IO Rf-160/480 (Part D2) | MEL 1L-160/480 (Part E) | MEL 1L-480/480 (Part E) | MEL Prior IO rf - 480/480 (Part E) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Part C, D1, D2, E - Disease Control Rate (DCR) Per Investigator | 62.5 (40.6 to 81.2) | 62.1 (49.3 to 73.8) | 46.2 (26.6 to 66.6) | 50.8 (38.1 to 63.4) | 54.0 (40.9 to 66.6) | 32.3 (22.9 to 42.7) | 50.0 (32.9 to 67.1) | 38.6 (26.0 to 52.4) | 42.7 (34.6 to 51.0) | 44.1 (36.8 to 51.5) | 45.8 (34.8 to 57.1) | 45.1 (34.1 to 56.5) | 39.6 (32.1 to 47.6) | 55.3 (43.4 to 66.7) | 68.8 (57.3 to 78.9) | 43.6 (33.4 to 54.2) |
DOR for a participant with a best overall response (BOR) of CR or PR is defined as the time between the date of first response and the date of the first objectively documented tumor progression by investigator per response evaluation criteria in solid tumors (RECIST) v1.1 or death, whichever occurs first. Median computed using Kaplan-Meier method. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\\< 10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum during the study (this includes the baseline sum). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
| months | NSCLC IO Naive-80/240 (Part C) | MEL 1L-80/240 (Part C) | RCC IO Naive-80/240 (Part C) | SCCHN IO Naive-80/240 (Part C) | HCC IO Naive-80/240 (Part C) | Gastric IO Naive-80/240 (Part C) | Bladder IO Naive-160/480 (Part C) | NSCLC Prior IO-80/240 (Part C) | MEL Prior IO - 80/240 (Part C) | MEL Prior IO Rf-80/240 Q2W (Part D1 Coad) | MEL Prior IO Rf-160/480 Q4W (Part D1 Coad) | MEL Prior IO Rf-160/480 (Part D1 FDC) | MEL Prior IO Rf-160/480 (Part D2) | MEL 1L-160/480 (Part E) | MEL 1L-480/480 (Part E) | MEL Prior IO rf - 480/480 (Part E) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Part C, D1, D2, E - Duration of Response (DOR) Per Investigator | 15.3 (5.3 to 57.2) | NA (3.7 to 67.9) | NA (3.0 to 58.3) | 14.0 (3.7 to 59.8) | 53.4 (3.7 to 75.5) | 5.7 (2.4 to 62.6) | 16.8 (6.6 to 57.9) | 7.1 (5.6 to 8.6) | NA (4.0 to 79.0) | 27.5 (1.0 to 75.7) | 31.5 (2.6 to 46.3) | NA (5.5 to 70.1) | 18.9 (3.8 to 60.8) | NA (6.5 to 60.7) | NA (6.5 to 57.2) | 14.5 (2.0 to 57.0) |
Progression Free Survival Rates up to 12 months is defined as the proportion of participants who achieve PFS up to 12 months. PFS for a participant is defined as the time from randomization date to the date of first objectively documented disease progression by investigator per response evaluation criteria in solid tumors (RECIST) v1.1 or death due to any cause, whichever occurs first. Based on Kaplan-Meier Estimates. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum during the study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
| proportion of participants | NSCLC IO Naive-80/240 (Part C) | MEL 1L-80/240 (Part C) | RCC IO Naive-80/240 (Part C) | SCCHN IO Naive-80/240 (Part C) | HCC IO Naive-80/240 (Part C) | Gastric IO Naive-80/240 (Part C) | Bladder IO Naive-160/480 (Part C) | NSCLC Prior IO-80/240 (Part C) | MEL Prior IO - 80/240 (Part C) | MEL Prior IO Rf-80/240 Q2W (Part D1 Coad) | MEL Prior IO Rf-160/480 Q4W (Part D1 Coad) | MEL Prior IO Rf-160/480 (Part D1 FDC) | MEL Prior IO Rf-160/480 (Part D2) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Part C, D1 and D2: Progression-Free Survival (PFS) Rate Per Investigator | 0.29 (0.12 to 0.49) | 0.47 (0.35 to 0.59) | 0.33 (0.15 to 0.53) | 0.20 (0.11 to 0.31) | 0.18 (0.10 to 0.29) | 0.06 (0.02 to 0.12) | 0.32 (0.18 to 0.48) | 0.16 (0.08 to 0.27) | 0.14 (0.09 to 0.20) | 0.17 (0.12 to 0.23) | 0.10 (0.05 to 0.18) | 0.21 (0.13 to 0.30) | 0.14 (0.09 to 0.21) |
Blood samples were collected to assess anti-drug antibodies.
| Participants | BMS-986016 (Relatlimab) Monotherapy 20 Milligram (mg) (Part A) | BMS-986016 (Relatlimab) Monotherapy 80 Milligram (mg | BMS-986016 (Relatlimab) Monotherapy 240 Milligram (mg) (Part A) | BMS-986016 (Relatlimab) Monotherapy 800 Milligram (mg) (Part A/A1) | Combination-Escalation-BMS-986016 (Relatlimab)/Nivolumab (20 mg/80 mg) (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (20 mg/240 mg (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (80 mg/240 mg) (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (160 mg/240 mg) (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (240 mg/240 mg) (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (160 mg/480 mg) (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (240 mg/480 mg) (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (320 mg/480 mg) (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (480 mg/480 mg) (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (960 mg/480 mg) (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (1440 mg/480 mg) (Part B) | NSCLC IO Naive-80/240 (Part C) | MEL 1L-80/240 (Part C) | RCC IO Naive-80/240 (Part C) | SCCHN IO Naive-80/240 (Part C) | HCC IO Naive-80/240 (Part C) | Gastric IO Naive-80/240 (Part C) | Bladder IO Naive-160/480 (Part C) | NSCLC Prior IO-80/240 (Part C) | MEL Prior IO - 80/240 (Part C) | MEL Prior IO Rf-80/240 Q2W (Part D1 Coad) | MEL Prior IO Rf-160/480 Q4W (Part D1 Coad) | MEL Prior IO Rf-160/480 (Part D1 FDC) | MEL Prior IO Rf-160/480 (Part D2) | MEL Prior IO rf - 480/480 (Part E) | MEL 1L-160/480 (Part E) | MEL 1L-480/480 (Part E) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| relatlimab | 0 | 0 | 0 | 0 | 2 | 2 | 1 | 2 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 5 | 12 | 6 | 7 | 19 | 11 | 3 | 7 | 21 | 4 | 3 | 2 | 2 | 0 | 5 | 0 |
| Nivolumab | — | — | — | — | 1 | 0 | 1 | 2 | 1 | 1 | 1 | 0 | 0 | 3 | 0 | 6 | 9 | 2 | 18 | 18 | 16 | 4 | 4 | 18 | 9 | 2 | 0 | 4 | 3 | 7 | 4 |
Abnormal electrocardiogram parameter included QT prolongation.
| Participants | BMS-986016 (Relatlimab) Monotherapy 20 Milligram (mg) (Part A) | BMS-986016 (Relatlimab) Monotherapy 80 Milligram (mg | BMS-986016 (Relatlimab) Monotherapy 240 Milligram (mg) (Part A) | BMS-986016 (Relatlimab) Monotherapy 800 Milligram (mg) (Part A/A1) | Combination-Escalation-BMS-986016 (Relatlimab)/Nivolumab (20 mg/80 mg) (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (20 mg/240 mg (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (80 mg/240 mg) (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (160 mg/240 mg) (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (240 mg/240 mg) (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (160 mg/480 mg) (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (240 mg/480 mg) (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (320 mg/480 mg) (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (480 mg/480 mg) (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (960 mg/480 mg) (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (1440 mg/480 mg) (Part B) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Part A, A/A1, and B: Number of Participants With Clinically Relevant QT Prolongation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Blood samples were collected for assessment of pharmacokinetic parameter of BMS-986016 (relatlimab).
| microgram per milliliter (UG/ML) | BMS-986016 (Relatlimab) Monotherapy 20 Milligram (mg) (Part A) | BMS-986016 (Relatlimab) Monotherapy 80 Milligram (mg | BMS-986016 (Relatlimab) Monotherapy 240 Milligram (mg) (Part A) | BMS-986016 (Relatlimab) Monotherapy 800 Milligram (mg) (Part A/A1) | Combination-Escalation-BMS-986016 (Relatlimab)/Nivolumab (20 mg/80 mg) (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (20 mg/240 mg (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (80 mg/240 mg) (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (160 mg/240 mg) (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (240 mg/240 mg) (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (160 mg/480 mg) (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (240 mg/480 mg) (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (320 mg/480 mg) (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (480 mg/480 mg) (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (960 mg/480 mg) (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (1440 mg/480 mg) (Part B) | NSCLC IO Naive-80/240 (Part C) | MEL 1L-80/240 (Part C) | RCC IO Naive-80/240 (Part C) | SCCHN IO Naive-80/240 (Part C) | HCC IO Naive-80/240 (Part C) | Gastric IO Naive-80/240 (Part C) | Bladder IO Naive-160/480 (Part C) | NSCLC Prior IO-80/240 (Part C) | MEL Prior IO - 80/240 (Part C) | MEL Prior IO Rf-80/240 Q2W (Part D1 Coad) | MEL Prior IO Rf-160/480 Q4W (Part D1 Coad) | MEL Prior IO Rf-160/480 (Part D1 FDC) | MEL Prior IO Rf-160/480 (Part D2) | MEL Prior IO rf - 480/480 (Part E) | MEL 1L-160/480 (Part E) | MEL 1L-480/480 (Part E) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Day 1 of Cycle 1 | 5.501 ± 26 | 27.528 ± 33 | 69.761 ± 32 | 272.554 ± 29 | 5.762 ± 21 | 7.038 ± 27 | 27.722 ± 77 | 48.441 ± 53 | 49.918 ± 31 | 33.873 ± 19 | 53.552 ± 33 | 91.099 ± 23 | 100.873 ± 25 | 280.299 ± 27 | 427.427 ± 16 | 17.580 ± 22 | 20.834 ± 30 | 18.031 ± 24 | 21.377 ± 30 | 20.849 ± 37 | 17.840 ± 36 | 53.762 ± 10 | 19.703 ± 23 | 17.757 ± 26 | — | 48.214 ± 24 | 44.735 ± 21 | — | — | — | — |
| Day 1 of Cycle 3 | 8.890 ± NA | — | — | 527.000 ± NA | 8.138 ± 64 | 8.578 ± 17 | 46.346 ± 35 | 86.558 ± 13 | 95.000 ± NA | 43.454 ± 7 | 104.000 ± NA | 237.199 ± 108 | 160.000 ± NA | — | 595.364 ± 55 | 43.135 ± 4 | 35.495 ± 17 | 40.758 ± 38 | 38.920 ± 29 | 31.015 ± 33 | 25.846 ± 2 | 82.188 ± 2 | 37.771 ± 20 | 33.977 ± 39 | — | — | — | — | — | — | — |
Blood samples were collected for assessment of pharmacokinetic parameter of BMS-986016 (relatlimab).
| hours | BMS-986016 (Relatlimab) Monotherapy 20 Milligram (mg) (Part A) | BMS-986016 (Relatlimab) Monotherapy 80 Milligram (mg | BMS-986016 (Relatlimab) Monotherapy 240 Milligram (mg) (Part A) | BMS-986016 (Relatlimab) Monotherapy 800 Milligram (mg) (Part A/A1) | Combination-Escalation-BMS-986016 (Relatlimab)/Nivolumab (20 mg/80 mg) (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (20 mg/240 mg (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (80 mg/240 mg) (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (160 mg/240 mg) (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (240 mg/240 mg) (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (160 mg/480 mg) (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (240 mg/480 mg) (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (320 mg/480 mg) (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (480 mg/480 mg) (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (960 mg/480 mg) (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (1440 mg/480 mg) (Part B) | NSCLC IO Naive-80/240 (Part C) | MEL 1L-80/240 (Part C) | RCC IO Naive-80/240 (Part C) | SCCHN IO Naive-80/240 (Part C) | HCC IO Naive-80/240 (Part C) | Gastric IO Naive-80/240 (Part C) | Bladder IO Naive-160/480 (Part C) | NSCLC Prior IO-80/240 (Part C) | MEL Prior IO - 80/240 (Part C) | MEL Prior IO Rf-80/240 Q2W (Part D1 Coad) | MEL Prior IO Rf-160/480 Q4W (Part D1 Coad) | MEL Prior IO Rf-160/480 (Part D1 FDC) | MEL Prior IO Rf-160/480 (Part D2) | MEL Prior IO rf - 480/480 (Part E) | MEL 1L-160/480 (Part E) | MEL 1L-480/480 (Part E) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Day 1 of Cycle 1 | 3.173 ± 42 | 1.709 ± 92 | 9.700 ± 77 | 2.041 ± 68 | 2.988 ± 36 | 3.391 ± 126 | 2.757 ± 46 | 3.007 ± 138 | 5.599 ± 105 | 3.585 ± 133 | 2.240 ± 172 | 2.047 ± 68 | 4.644 ± 111 | 2.618 ± 284 | 2.179 ± 166 | 3.343 ± 29 | 3.391 ± 102 | 1.840 ± 66 | 1.911 ± 62 | 2.534 ± 134 | 2.578 ± 133 | 2.312 ± 59 | 2.611 ± 46 | 2.191 ± 183 | — | 2.585 ± 49 | 2.095 ± 63 | — | — | — | — |
| Day 1 of Cycle 3 | 22.283 ± NA | — | — | 4.000 ± NA | 1.983 ± 86 | 3.927 ± 139 | 1.414 ± 47 | 5.005 ± 131 | 4.000 ± NA | 5.083 ± 130 | 2.950 ± NA | 1.762 ± 78 | 4.167 ± NA | — | 2.045 ± 69 | 3.958 ± 1 | 4.455 ± 119 | 3.928 ± 9 | 1.858 ± 63 | 2.515 ± 69 | 4.000 ± 0 | 4.457 ± 15 | 3.917 ± 16 | 2.940 ± 34 | — | — | — | — | — | — | — |
Blood samples were collected for assessment of pharmacokinetic parameter of BMS-986016 (relatlimab).
| hours*ug/mL | BMS-986016 (Relatlimab) Monotherapy 20 Milligram (mg) (Part A) | BMS-986016 (Relatlimab) Monotherapy 80 Milligram (mg | BMS-986016 (Relatlimab) Monotherapy 240 Milligram (mg) (Part A) | BMS-986016 (Relatlimab) Monotherapy 800 Milligram (mg) (Part A/A1) | Combination-Escalation-BMS-986016 (Relatlimab)/Nivolumab (20 mg/80 mg) (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (20 mg/240 mg (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (80 mg/240 mg) (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (160 mg/240 mg) (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (240 mg/240 mg) (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (160 mg/480 mg) (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (240 mg/480 mg) (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (320 mg/480 mg) (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (480 mg/480 mg) (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (960 mg/480 mg) (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (1440 mg/480 mg) (Part B) | NSCLC IO Naive-80/240 (Part C) | MEL 1L-80/240 (Part C) | RCC IO Naive-80/240 (Part C) | SCCHN IO Naive-80/240 (Part C) | HCC IO Naive-80/240 (Part C) | Gastric IO Naive-80/240 (Part C) | Bladder IO Naive-160/480 (Part C) | NSCLC Prior IO-80/240 (Part C) | MEL Prior IO - 80/240 (Part C) | MEL Prior IO Rf-80/240 Q2W (Part D1 Coad) | MEL Prior IO Rf-160/480 Q4W (Part D1 Coad) | MEL Prior IO Rf-160/480 (Part D1 FDC) | MEL Prior IO Rf-160/480 (Part D2) | MEL Prior IO rf - 480/480 (Part E) | MEL 1L-160/480 (Part E) | MEL 1L-480/480 (Part E) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Day 1 of Cycle 1 | 686.264 ± 40 | 3308.767 ± 23 | 11848.262 ± 35 | 38183.302 ± 16 | 700.840 ± 32 | 756.154 ± 38 | 3395.923 ± 20 | 7153.802 ± 35 | 7594.275 ± 19 | 6076.663 ± 32 | 13473.538 ± 46 | 19658.643 ± 34 | 24397.911 ± 28 | 68106.909 ± 18 | 117532.665 ± 19 | 2374.750 ± 33 | 3237.956 ± 32 | 2550.155 ± 35 | 3040.426 ± 31 | 2548.992 ± 28 | 2584.823 ± 27 | 11525.303 ± 10 | 2848.132 ± 28 | 2586.229 ± 26 | — | 9890.685 ± 28 | 10641.828 ± 29 | — | — | — | — |
| Day 1 of Cycle 3 | — | — | — | 105538.444 ± NA | 1002.859 ± 84 | 1614.609 ± 42 | 6205.354 ± NA | 17913.840 ± 45 | 21182.662 ± NA | — | — | 34467.380 ± 40 | 48155.384 ± NA | — | 144555.686 ± 16 | 8838.930 ± NA | 8607.003 ± NA | 5325.430 ± NA | 8786.513 ± 32 | 2909.162 ± NA | 5374.646 ± NA | 23004.311 ± 4 | 7147.642 ± 28 | 6864.659 ± 53 | — | — | — | — | — | — | — |
Blood samples were collected for assessment of pharmacokinetic parameter of BMS-986016 (relatlimab). Ctrough is defined as the lowest concentration of drug in the blood immediately before the next dose is administered. Ctrough was only assessed for arm Part A/A1, B, C, D1, D2 and E as pre-specified.
| ug/mL | BMS-986016 (Relatlimab) Monotherapy 800 Milligram (mg) (Part A/A1) | Combination-Escalation-BMS-986016 (Relatlimab)/Nivolumab (20 mg/80 mg) (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (20 mg/240 mg (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (80 mg/240 mg) (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (160 mg/240 mg) (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (240 mg/240 mg) (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (160 mg/480 mg) (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (240 mg/480 mg) (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (320 mg/480 mg) (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (480 mg/480 mg) (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (960 mg/480 mg) (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (1440 mg/480 mg) (Part B) | NSCLC IO Naive-80/240 (Part C) | MEL 1L-80/240 (Part C) | RCC IO Naive-80/240 (Part C) | SCCHN IO Naive-80/240 (Part C) | HCC IO Naive-80/240 (Part C) | Gastric IO Naive-80/240 (Part C) | Bladder IO Naive-160/480 (Part C) | NSCLC Prior IO-80/240 (Part C) | MEL Prior IO - 80/240 (Part C) | MEL Prior IO Rf-80/240 Q2W (Part D1 Coad) | MEL Prior IO Rf-160/480 Q4W (Part D1 Coad) | MEL Prior IO Rf-160/480 (Part D1 FDC) | MEL Prior IO Rf-160/480 (Part D2) | MEL Prior IO rf - 480/480 (Part E) | MEL 1L-160/480 (Part E) | MEL 1L-480/480 (Part E) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Part A/A1, B, C, D1, D2 and E: Trough Observed Concentration (Ctrough) of BMS-986016 (Relatlimab) | 215.000 ± NA | 1.283 ± 107 | 1.597 ± 73 | 14.176 ± 83 | 38.174 ± 50 | 46.600 ± NA | 2.656 ± 126 | 40.690 ± 63 | 19.239 ± 75 | 21.400 ± NA | 98.000 ± NA | 212.230 ± 34 | 13.929 ± 45 | 13.317 ± 57 | 15.192 ± 60 | 15.138 ± 39 | 5.556 ± 93 | 13.514 ± 46 | 8.364 ± 64 | 12.621 ± 47 | 16.119 ± 173 | 15.239 ± 48 | 10.084 ± 54 | 67.329 ± 55 | 13.201 ± 63 | 48.055 ± 44 | 10.842 ± 59 | 63.314 ± 26 |
Blood samples were collected for assessment of pharmacokinetic parameter of BMS-986016 (relatlimab). CLT was only assessed for arm Part A/A1, B, C as pre-specified.
| mL/h | BMS-986016 (Relatlimab) Monotherapy 800 Milligram (mg) (Part A/A1) | Combination-Escalation-BMS-986016 (Relatlimab)/Nivolumab (20 mg/80 mg) (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (20 mg/240 mg (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (80 mg/240 mg) (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (160 mg/240 mg) (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (240 mg/240 mg) (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (160 mg/480 mg) (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (240 mg/480 mg) (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (320 mg/480 mg) (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (480 mg/480 mg) (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (960 mg/480 mg) (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (1440 mg/480 mg) (Part B) | NSCLC IO Naive-80/240 (Part C) | MEL 1L-80/240 (Part C) | RCC IO Naive-80/240 (Part C) | SCCHN IO Naive-80/240 (Part C) | HCC IO Naive-80/240 (Part C) | Gastric IO Naive-80/240 (Part C) | Bladder IO Naive-160/480 (Part C) | NSCLC Prior IO-80/240 (Part C) | MEL Prior IO - 80/240 (Part C) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Part A/A1, B, CTotal Body Clearance (CLT) of BMS-986016 (Relatlimab) | 7.580 ± NA | 19.943 ± 84 | 12.387 ± 42 | 12.892 ± NA | 8.932 ± 45 | 11.330 ± NA | NA ± NA | NA ± NA | 9.284 ± 40 | 9.968 ± NA | NA ± NA | 9.962 ± 16 | 9.051 ± NA | 9.295 ± NA | 15.022 ± NA | 9.105 ± 32 | 27.499 ± NA | 14.885 ± NA | 6.955 ± 4 | 11.193 ± 33 | 11.654 ± 39 |
Blood samples were collected for assessment of pharmacokinetic parameter of BMS-986016 (relatlimab). AUC Accumulation Index is a pharmacokinetic metric used to quantify how much a drug accumulates in the body after repeated dosing compared to a single dose. It is ratio of AUC Steady State (AUCss) and AUC1. AUCₛₛ is the area under the plasma concentration-time curve during a dosing interval at steady state (after repeated doses). AUC₁ is the area under the curve after a single dose. Only assessed for arm Part A/A1, B, C as pre-specified.
| Ratio of AUCss and AUC1 | BMS-986016 (Relatlimab) Monotherapy 800 Milligram (mg) (Part A/A1) | Combination-Escalation-BMS-986016 (Relatlimab)/Nivolumab (20 mg/80 mg) (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (20 mg/240 mg (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (80 mg/240 mg) (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (160 mg/240 mg) (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (240 mg/240 mg) (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (160 mg/480 mg) (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (240 mg/480 mg) (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (320 mg/480 mg) (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (480 mg/480 mg) (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (960 mg/480 mg) (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (1440 mg/480 mg) (Part B) | NSCLC IO Naive-80/240 (Part C) | MEL 1L-80/240 (Part C) | RCC IO Naive-80/240 (Part C) | SCCHN IO Naive-80/240 (Part C) | HCC IO Naive-80/240 (Part C) | Gastric IO Naive-80/240 (Part C) | Bladder IO Naive-160/480 (Part C) | NSCLC Prior IO-80/240 (Part C) | MEL Prior IO - 80/240 (Part C) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Part A/A1, B, C AUC Accumulation Index AI_AUC of BMS-986016 (Relatlimab) | 2.433 ± NA | NA ± NA | 1.825 ± 4 | 1.985 ± NA | 3.143 ± 36 | NA ± NA | NA ± NA | NA ± NA | 1.376 ± 54 | 1.606 ± NA | NA ± NA | 1.331 ± NA | 2.993 ± NA | 2.910 ± NA | 2.317 ± NA | 2.760 ± 32 | 1.525 ± NA | 2.131 ± NA | 1.877 ± 3 | 2.037 ± 33 | 2.550 ± 36 |
Collected over All-cause mortality was collected from first dose (Day 1) and up to approximately 89 months. SAEs and Other AEs were collected from first dose and within 135 days after last dose of study therapy (Up to approximately 82 months).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| BMS-986016 (Relatlimab) Monotherapy 20 Milligram (mg) (Part A) | 5/5 (100%) | 5/5 (100%) | 5/5 (100%) |
| BMS-986016 (Relatlimab) Monotherapy 80 Milligram (mg) (Part A) | 3/4 (75%) | 3/4 (75%) | 4/4 (100%) |
| EBMS-986016 (Relatlimab) Monotherapy 240 Milligram (mg) (Part A) | 4/4 (100%) | 3/4 (75%) | 4/4 (100%) |
| BMS-986016 (Relatlimab) Monotherapy 800 Milligram (mg) (Part A) | 3/4 (75%) | 2/4 (50%) | 4/4 (100%) |
| Combination-Escalation-BMS-986016 (Relatlimab)/Nivolumab (20 mg/80 mg) (Part B) | 5/7 (71.4%) | 5/7 (71.4%) | 7/7 (100%) |
| Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (20 mg/240 mg (Part B) | 7/9 (77.8%) | 7/9 (77.8%) | 9/9 (100%) |
| Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (80 mg/240 mg) (Part B) | 6/8 (75%) | 6/8 (75%) | 8/8 (100%) |
| Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (160 mg/240 mg) (Part B) | 7/8 (87.5%) | 6/8 (75%) | 7/8 (87.5%) |
| Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (240 mg/240 mg) (Part B) | 6/8 (75%) | 7/8 (87.5%) | 8/8 (100%) |
| Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (160 mg/480 mg) (Part B) | 8/8 (100%) | 5/8 (62.5%) | 7/8 (87.5%) |
| MEL 1L-160/480 (Part E) | 27/77 (35.1%) | 49/77 (63.6%) | 74/77 (96.1%) |
| Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (240 mg/480 mg) (Part B) | 6/8 (75%) | 5/8 (62.5%) | 8/8 (100%) |
| Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (320 mg/480 mg) (Part B) | 6/8 (75%) | 6/8 (75%) | 8/8 (100%) |
| Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (480 mg/480 mg) (Part B) | 4/7 (57.1%) | 3/7 (42.9%) | 7/7 (100%) |
| MEL Prior IO rf - 480/480 (Part E)MEL 1L-480/480 (Part E) | 83/95 (87.4%) | 70/95 (73.7%) | 88/95 (92.6%) |
| MEL 1L-480/480 (Part E) | 33/77 (42.9%) | 47/77 (61%) | 74/77 (96.1%) |
| Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (960 mg/480 mg) (Part B) | 17/17 (100%) | 10/17 (58.8%) | 16/17 (94.1%) |
| Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (1440 mg/480 mg) (Part B) | 14/19 (73.7%) | 12/19 (63.2%) | 19/19 (100%) |
| BMS-986016 (Relatlimab) Expansion (NSCLC) 800 mg (Part A1) | 4/4 (100%) | 3/4 (75%) | 4/4 (100%) |
| BMS-986016 (Relatlimab) Expansion (RCC) 800 mg (Part A1) | 4/4 (100%) | 2/4 (50%) | 4/4 (100%) |
| MEL 1L-80/240 (Part C) | 37/66 (56.1%) | 38/66 (57.6%) | 56/66 (84.8%) |
| MEL Prior IO - 80/240 (Part C) | 117/151 (77.5%) | 98/151 (64.9%) | 124/151 (82.1%) |
| NSCLC Prior IO-80/240 (Part C) | 17/24 (70.8%) | 15/24 (62.5%) | 21/24 (87.5%) |
| NSCLC Prior IO-80/240 (Part C)-rf | 31/32 (96.9%) | 21/32 (65.6%) | 30/32 (93.8%) |
| NSCLC Prior IO-80/240 (Part C)-rl | 24/25 (96%) | 15/25 (60%) | 23/25 (92%) |
| SCCHN IO Naive-80/240 (Part C) | 57/65 (87.7%) | 44/65 (67.7%) | 62/65 (95.4%) |
| Gastric IO Naive-80/240 (Part C) | 80/94 (85.1%) | 69/94 (73.4%) | 89/94 (94.7%) |
| RCC IO Naive-80/240 (Part C) | 17/26 (65.4%) | 17/26 (65.4%) | 24/26 (92.3%) |
| HCC IO Naive-80/240 (Part C) | 49/63 (77.8%) | 49/63 (77.8%) | 61/63 (96.8%) |
| Bladder IO Naive-160/480 (Part C) | 29/37 (78.4%) | 28/37 (75.7%) | 30/37 (81.1%) |
| MEL Prior IO Rf-80/240 Q2W (Part D1 Coad) | 156/189 (82.5%) | 118/189 (62.4%) | 178/189 (94.2%) |
| MEL Prior IO Rf-160/480 Q4W (Part D1 Coad) | 71/83 (85.5%) | 58/83 (69.9%) | 77/83 (92.8%) |
| MEL Prior IO Rf-160/480 (Part D2) | 135/164 (82.3%) | 113/164 (68.9%) | 156/164 (95.1%) |
| MEL Prior IO Rf-160/480 (Part D1 FDC) | 64/82 (78%) | 49/82 (59.8%) | 77/82 (93.9%) |
| Event | BMS-986016 (Relatlimab) Monotherapy 20 Milligram (mg) (Part A) | BMS-986016 (Relatlimab) Monotherapy 80 Milligram (mg) (Part A) | EBMS-986016 (Relatlimab) Monotherapy 240 Milligram (mg) (Part A) | BMS-986016 (Relatlimab) Monotherapy 800 Milligram (mg) (Part A) | Combination-Escalation-BMS-986016 (Relatlimab)/Nivolumab (20 mg/80 mg) (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (20 mg/240 mg (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (80 mg/240 mg) (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (160 mg/240 mg) (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (240 mg/240 mg) (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (160 mg/480 mg) (Part B) | MEL 1L-160/480 (Part E) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (240 mg/480 mg) (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (320 mg/480 mg) (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (480 mg/480 mg) (Part B) | MEL Prior IO rf - 480/480 (Part E)MEL 1L-480/480 (Part E) | MEL 1L-480/480 (Part E) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (960 mg/480 mg) (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (1440 mg/480 mg) (Part B) | BMS-986016 (Relatlimab) Expansion (NSCLC) 800 mg (Part A1) | BMS-986016 (Relatlimab) Expansion (RCC) 800 mg (Part A1) | MEL 1L-80/240 (Part C) | MEL Prior IO - 80/240 (Part C) | NSCLC Prior IO-80/240 (Part C) | NSCLC Prior IO-80/240 (Part C)-rf | NSCLC Prior IO-80/240 (Part C)-rl | SCCHN IO Naive-80/240 (Part C) | Gastric IO Naive-80/240 (Part C) | RCC IO Naive-80/240 (Part C) | HCC IO Naive-80/240 (Part C) | Bladder IO Naive-160/480 (Part C) | MEL Prior IO Rf-80/240 Q2W (Part D1 Coad) | MEL Prior IO Rf-160/480 Q4W (Part D1 Coad) | MEL Prior IO Rf-160/480 (Part D2) | MEL Prior IO Rf-160/480 (Part D1 FDC) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 5/5 | 3/4 | 1/4 | 1/4 | 3/7 | 5/9 | 4/8 | 2/8 | 5/8 | 2/8 | 11/77 | 2/8 | 1/8 | 2/7 | 30/95 | 7/77 | 2/17 | 7/19 | 2/4 | 2/4 | 12/66 | 59/151 | 6/24 | 8/32 | 8/25 | 21/65 | 44/94 | 7/26 | 19/63 | 14/37 | 60/189 | 23/83 | 53/164 | 24/82 |
| TachycardiaCardiac disorders | 0/5 | 0/4 | 1/4 | 0/4 | 0/7 | 0/9 | 0/8 | 0/8 | 0/8 | 0/8 | 0/77 | 0/8 | 0/8 | 0/7 | 0/95 | 0/77 | 0/17 | 0/19 | 0/4 | 0/4 | 1/66 | 0/151 | 0/24 | 0/32 | 0/25 | 0/65 | 0/94 | 0/26 | 0/63 | 0/37 | 0/189 | 0/83 | 1/164 | 0/82 |
| Abdominal painGastrointestinal disorders | 0/5 | 1/4 | 0/4 | 0/4 | 1/7 | 1/9 | 1/8 | 0/8 | 1/8 | 0/8 | 1/77 | 0/8 | 0/8 | 0/7 | 3/95 | 2/77 | 0/17 | 0/19 | 0/4 | 0/4 | 0/66 | 1/151 | 0/24 | 0/32 | 0/25 | 0/65 | 3/94 | 1/26 | 2/63 | 1/37 | 5/189 | 1/83 | 5/164 | 0/82 |
| ConstipationGastrointestinal disorders | 0/5 | 0/4 | 0/4 | 0/4 | 0/7 | 0/9 | 1/8 | 0/8 | 0/8 | 0/8 | 0/77 | 0/8 | 0/8 | 0/7 | 0/95 | 0/77 | 0/17 | 0/19 | 0/4 | 1/4 | 0/66 | 1/151 | 0/24 | 0/32 | 1/25 | 0/65 | 1/94 | 0/26 | 0/63 | 0/37 | 1/189 | 0/83 | 3/164 | 1/82 |
| DiarrhoeaGastrointestinal disorders | 1/5 | 0/4 | 0/4 | 1/4 | 0/7 | 0/9 | 0/8 | 0/8 | 0/8 | 2/8 | 0/77 | 0/8 | 0/8 | 0/7 | 1/95 | 1/77 | 0/17 | 0/19 | 0/4 | 0/4 | 1/66 | 0/151 | 0/24 | 1/32 | 0/25 | 0/65 | 1/94 | 0/26 | 1/63 | 1/37 | 4/189 | 2/83 | 2/164 | 1/82 |
| DeathGeneral disorders | 0/5 | 0/4 | 1/4 | 0/4 | 0/7 | 0/9 | 0/8 | 0/8 | 0/8 | 0/8 | 0/77 | 0/8 | 0/8 | 0/7 | 1/95 | 0/77 | 0/17 | 0/19 | 0/4 | 0/4 | 0/66 | 1/151 | 0/24 | 0/32 | 0/25 | 0/65 | 0/94 | 0/26 | 0/63 | 0/37 | 1/189 | 0/83 | 0/164 | 1/82 |
| FatigueGeneral disorders | 0/5 | 1/4 | 0/4 | 0/4 | 0/7 | 0/9 | 0/8 | 0/8 | 1/8 | 0/8 | 0/77 | 0/8 | 0/8 | 0/7 | 0/95 | 3/77 | 0/17 | 0/19 | 0/4 | 0/4 | 0/66 | 0/151 | 0/24 | 1/32 | 0/25 | 0/65 | 1/94 | 0/26 | 2/63 | 0/37 | 2/189 | 0/83 | 0/164 | 1/82 |
| Non-cardiac chest painGeneral disorders | 0/5 | 0/4 | 0/4 | 0/4 | 0/7 | 0/9 | 0/8 | 0/8 | 0/8 | 0/8 | 0/77 | 0/8 | 0/8 | 0/7 | 0/95 | 0/77 | 0/17 | 0/19 | 1/4 | 0/4 | 0/66 | 1/151 | 0/24 | 0/32 | 0/25 | 0/65 | 0/94 | 0/26 | 0/63 | 0/37 | 1/189 | 1/83 | 0/164 | 0/82 |
| PyrexiaGeneral disorders | 0/5 | 0/4 | 0/4 | 0/4 | 0/7 | 0/9 | 0/8 | 0/8 | 0/8 | 0/8 | 0/77 | 0/8 | 0/8 | 0/7 | 3/95 | 1/77 | 0/17 | 2/19 | 0/4 | 1/4 | 2/66 | 6/151 | 0/24 | 1/32 | 0/25 | 0/65 | 2/94 | 0/26 | 3/63 | 0/37 | 10/189 | 0/83 | 6/164 | 0/82 |
| Drug hypersensitivityImmune system disorders | 0/5 | 0/4 | 0/4 | 0/4 | 0/7 | 0/9 | 0/8 | 0/8 | 0/8 | 0/8 | 0/77 | 0/8 | 0/8 | 0/7 | 0/95 | 0/77 | 0/17 | 0/19 | 0/4 | 1/4 | 0/66 | 0/151 | 0/24 | 0/32 | 0/25 | 0/65 | 0/94 | 0/26 | 1/63 | 0/37 | 0/189 | 0/83 | 0/164 | 0/82 |
| Event | BMS-986016 (Relatlimab) Monotherapy 20 Milligram (mg) (Part A) | BMS-986016 (Relatlimab) Monotherapy 80 Milligram (mg) (Part A) | EBMS-986016 (Relatlimab) Monotherapy 240 Milligram (mg) (Part A) | BMS-986016 (Relatlimab) Monotherapy 800 Milligram (mg) (Part A) | Combination-Escalation-BMS-986016 (Relatlimab)/Nivolumab (20 mg/80 mg) (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (20 mg/240 mg (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (80 mg/240 mg) (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (160 mg/240 mg) (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (240 mg/240 mg) (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (160 mg/480 mg) (Part B) | MEL 1L-160/480 (Part E) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (240 mg/480 mg) (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (320 mg/480 mg) (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (480 mg/480 mg) (Part B) | MEL Prior IO rf - 480/480 (Part E)MEL 1L-480/480 (Part E) | MEL 1L-480/480 (Part E) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (960 mg/480 mg) (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (1440 mg/480 mg) (Part B) | BMS-986016 (Relatlimab) Expansion (NSCLC) 800 mg (Part A1) | BMS-986016 (Relatlimab) Expansion (RCC) 800 mg (Part A1) | MEL 1L-80/240 (Part C) | MEL Prior IO - 80/240 (Part C) | NSCLC Prior IO-80/240 (Part C) | NSCLC Prior IO-80/240 (Part C)-rf | NSCLC Prior IO-80/240 (Part C)-rl | SCCHN IO Naive-80/240 (Part C) | Gastric IO Naive-80/240 (Part C) | RCC IO Naive-80/240 (Part C) | HCC IO Naive-80/240 (Part C) | Bladder IO Naive-160/480 (Part C) | MEL Prior IO Rf-80/240 Q2W (Part D1 Coad) | MEL Prior IO Rf-160/480 Q4W (Part D1 Coad) | MEL Prior IO Rf-160/480 (Part D2) | MEL Prior IO Rf-160/480 (Part D1 FDC) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 1/5 | 2/4 | 1/4 | 2/4 | 4/7 | 3/9 | 3/8 | 2/8 | 1/8 | 2/8 | 20/77 | 2/8 | 1/8 | 4/7 | 21/95 | 24/77 | 6/17 | 6/19 | 3/4 | 0/4 | 15/66 | 37/151 | 3/24 | 7/32 | 5/25 | 9/65 | 25/94 | 2/26 | 16/63 | 4/37 | 40/189 | 20/83 | 41/164 | 21/82 |
| FatigueGeneral disorders | 2/5 | 0/4 | 3/4 | 2/4 | 3/7 | 3/9 | 3/8 | 2/8 | 3/8 | 3/8 | 28/77 | 4/8 | 2/8 | 4/7 | 34/95 | 40/77 | 7/17 | 6/19 | 2/4 | 0/4 | 23/66 | 42/151 | 6/24 | 14/32 | 9/25 | 13/65 | 37/94 | 12/26 | 17/63 | 7/37 | 48/189 | 23/83 | 48/164 | 24/82 |
| Back painMusculoskeletal and connective tissue disorders | 1/5 | 1/4 | 1/4 | 0/4 | 2/7 | 0/9 | 0/8 | 1/8 | 2/8 | 1/8 | 6/77 | 1/8 | 3/8 | 2/7 | 8/95 | 16/77 | 3/17 | 2/19 | 1/4 | 3/4 | 13/66 | 11/151 | 4/24 | 1/32 | 5/25 | 1/65 | 10/94 | 5/26 | 10/63 | 2/37 | 14/189 | 13/83 | 21/164 | 11/82 |
| DizzinessNervous system disorders | 0/5 | 1/4 | 0/4 | 3/4 | 0/7 | 0/9 | 1/8 | 4/8 | 2/8 | 1/8 | 5/77 | 2/8 | 2/8 | 1/7 | 2/95 | 10/77 | 1/17 | 3/19 | 2/4 | 0/4 | 4/66 | 12/151 | 0/24 | 3/32 | 0/25 | 2/65 | 3/94 | 3/26 | 6/63 | 0/37 | 11/189 | 8/83 | 7/164 | 3/82 |
| HeadacheNervous system disorders | 0/5 | 0/4 | 0/4 | 3/4 | 1/7 | 1/9 | 1/8 | 2/8 | 2/8 | 1/8 | 15/77 | 1/8 | 1/8 | 1/7 | 10/95 | 13/77 | 2/17 | 3/19 | 1/4 | 0/4 | 14/66 | 22/151 | 2/24 | 2/32 | 0/25 | 7/65 | 5/94 | 4/26 | 3/63 | 3/37 | 19/189 | 14/83 | 24/164 | 9/82 |
| Decreased appetiteMetabolism and nutrition disorders | 3/5 | 1/4 | 1/4 | 1/4 | 4/7 | 1/9 | 2/8 | 3/8 | 4/8 | 2/8 | 16/77 | 1/8 | 1/8 | 2/7 | 14/95 | 9/77 | 5/17 | 5/19 | 2/4 | 0/4 | 14/66 | 20/151 | 3/24 | 6/32 | 2/25 | 12/65 | 20/94 | 5/26 | 13/63 | 7/37 | 37/189 | 12/83 | 24/164 | 11/82 |
| DiarrhoeaGastrointestinal disorders | 1/5 | 0/4 | 1/4 | 1/4 | 4/7 | 3/9 | 2/8 | 2/8 | 1/8 | 2/8 | 22/77 | 2/8 | 3/8 | 3/7 | 22/95 | 20/77 | 3/17 | 7/19 | 0/4 | 0/4 | 17/66 | 28/151 | 4/24 | 11/32 | 3/25 | 12/65 | 19/94 | 6/26 | 23/63 | 9/37 | 41/189 | 17/83 | 32/164 | 16/82 |
| PruritusSkin and subcutaneous tissue disorders | 0/5 | 1/4 | 0/4 | 0/4 | 0/7 | 0/9 | 2/8 | 2/8 | 1/8 | 2/8 | 20/77 | 2/8 | 3/8 | 4/7 | 17/95 | 27/77 | 6/17 | 4/19 | 2/4 | 0/4 | 12/66 | 24/151 | 6/24 | 3/32 | 2/25 | 8/65 | 5/94 | 4/26 | 10/63 | 8/37 | 23/189 | 18/83 | 28/164 | 11/82 |
| ConstipationGastrointestinal disorders | 0/5 | 1/4 | 0/4 | 1/4 | 3/7 | 1/9 | 4/8 | 0/8 | 1/8 | 1/8 | 14/77 | 4/8 | 1/8 | 1/7 | 13/95 | 17/77 | 5/17 | 4/19 | 0/4 | 1/4 | 9/66 | 13/151 | 6/24 | 5/32 | 3/25 | 10/65 | 26/94 | 1/26 | 10/63 | 1/37 | 34/189 | 13/83 | 26/164 | 13/82 |
| VomitingGastrointestinal disorders | 0/5 | 2/4 | 1/4 | 2/4 | 2/7 | 3/9 | 2/8 | 3/8 | 1/8 | 1/8 | 8/77 | 2/8 | 1/8 | 3/7 | 13/95 | 9/77 | 3/17 | 4/19 | 0/4 | 0/4 | 7/66 | 16/151 | 2/24 | 4/32 | 1/25 | 5/65 | 16/94 | 2/26 | 9/63 | 4/37 | 24/189 | 10/83 | 25/164 | 6/82 |
| Age, Customized(Participants) | BMS-986016 (Relatlimab) Monotherapy 20 Milligram (mg) (Part A) | BMS-986016 (Relatlimab) Monotherapy 80 Milligram (mg) (Part A) | BMS-986016 (Relatlimab) Monotherapy 240 Milligram (mg) (Part A) | BMS-986016 (Relatlimab) Monotherapy 800 Milligram (mg) (Part A/A1) | Combination-Escalation-BMS-986016 (Relatlimab)/Nivolumab (20 mg/80 mg) (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (20 mg/240 mg (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (80 mg/240 mg) (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (160 mg/240 mg) (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (240 mg/240 mg) (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (160 mg/480 mg) (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (240 mg/480 mg) (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (320 mg/480 mg) (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (480 mg/480 mg) (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (960 mg/480 mg) (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (1440 mg/480 mg) (Part B) | NSCLC IO Naive-80/240 (Part C) | MEL 1L-80/240 (Part C) | RCC IO Naive-80/240 (Part C) | SCCHN IO Naive-80/240 (Part C) | HCC IO Naive-80/240 (Part C) | Gastric IO Naive-80/240 (Part C) | Bladder IO Naive-160/480 (Part C) | NSCLC Prior IO-80/240 (Part C) | MEL Prior IO - 80/240 (Part C) | MEL Prior IO Rf-80/240 Q2W (Part D1 Coad) | MEL Prior IO Rf-160/480 Q4W (Part D1 Coad) | MEL Prior IO Rf-160/480 (Part D1 FDC) | MEL Prior IO Rf-160/480 (Part D2) | MEL 1L-160/480 (Part E) | MEL 1L-480/480 (Part E) | MEL Prior IO rf - 480/480 (Part E) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| < 65 years | 4 | 4 | 4 | 6 | 6 | 6 | 7 | 6 | 7 | 6 | 5 | 5 | 5 | 10 | 15 | 13 | 33 | 20 | 41 | 27 | 68 | 13 | 33 | 95 | 102 | 44 | 40 | 93 | 46 | 44 | 49 | 857 |
| >= 65 | 1 | 0 | 0 | 6 | 1 | 3 | 1 | 2 | 1 | 2 | 3 | 3 | 2 | 7 | 4 | 11 | 33 | 6 | 24 | 36 | 26 | 24 | 24 | 56 | 87 | 39 | 42 | 71 | 31 | 33 | 46 | 625 |
| Sex: Female, Male(Participants) | BMS-986016 (Relatlimab) Monotherapy 20 Milligram (mg) (Part A) | BMS-986016 (Relatlimab) Monotherapy 80 Milligram (mg) (Part A) | BMS-986016 (Relatlimab) Monotherapy 240 Milligram (mg) (Part A) | BMS-986016 (Relatlimab) Monotherapy 800 Milligram (mg) (Part A/A1) | Combination-Escalation-BMS-986016 (Relatlimab)/Nivolumab (20 mg/80 mg) (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (20 mg/240 mg (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (80 mg/240 mg) (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (160 mg/240 mg) (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (240 mg/240 mg) (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (160 mg/480 mg) (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (240 mg/480 mg) (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (320 mg/480 mg) (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (480 mg/480 mg) (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (960 mg/480 mg) (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (1440 mg/480 mg) (Part B) | NSCLC IO Naive-80/240 (Part C) | MEL 1L-80/240 (Part C) | RCC IO Naive-80/240 (Part C) | SCCHN IO Naive-80/240 (Part C) | HCC IO Naive-80/240 (Part C) | Gastric IO Naive-80/240 (Part C) | Bladder IO Naive-160/480 (Part C) | NSCLC Prior IO-80/240 (Part C) | MEL Prior IO - 80/240 (Part C) | MEL Prior IO Rf-80/240 Q2W (Part D1 Coad) | MEL Prior IO Rf-160/480 Q4W (Part D1 Coad) | MEL Prior IO Rf-160/480 (Part D1 FDC) | MEL Prior IO Rf-160/480 (Part D2) | MEL 1L-160/480 (Part E) | MEL 1L-480/480 (Part E) | MEL Prior IO rf - 480/480 (Part E) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 3 | 2 | 1 | 3 | 5 | 4 | 2 | 5 | 3 | 5 | 4 | 5 | 3 | 3 | 8 | 8 | 30 | 7 | 12 | 21 | 27 | 11 | 20 | 59 | 66 | 44 | 26 | 79 | 34 | 40 | 38 | 578 |
| Male | 2 | 2 | 3 | 9 | 2 | 5 | 6 | 3 | 5 | 3 | 4 | 3 | 4 | 14 | 11 | 16 | 36 | 19 | 53 | 42 | 67 | 26 | 37 | 92 | 123 | 39 | 56 | 85 | 43 | 37 | 57 | 904 |
| Ethnicity (NIH/OMB)(Participants) | BMS-986016 (Relatlimab) Monotherapy 20 Milligram (mg) (Part A) | BMS-986016 (Relatlimab) Monotherapy 80 Milligram (mg) (Part A) | BMS-986016 (Relatlimab) Monotherapy 240 Milligram (mg) (Part A) | BMS-986016 (Relatlimab) Monotherapy 800 Milligram (mg) (Part A/A1) | Combination-Escalation-BMS-986016 (Relatlimab)/Nivolumab (20 mg/80 mg) (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (20 mg/240 mg (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (80 mg/240 mg) (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (160 mg/240 mg) (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (240 mg/240 mg) (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (160 mg/480 mg) (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (240 mg/480 mg) (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (320 mg/480 mg) (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (480 mg/480 mg) (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (960 mg/480 mg) (Part B) | Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (1440 mg/480 mg) (Part B) | NSCLC IO Naive-80/240 (Part C) | MEL 1L-80/240 (Part C) | RCC IO Naive-80/240 (Part C) | SCCHN IO Naive-80/240 (Part C) | HCC IO Naive-80/240 (Part C) | Gastric IO Naive-80/240 (Part C) | Bladder IO Naive-160/480 (Part C) | NSCLC Prior IO-80/240 (Part C) | MEL Prior IO - 80/240 (Part C) | MEL Prior IO Rf-80/240 Q2W (Part D1 Coad) | MEL Prior IO Rf-160/480 Q4W (Part D1 Coad) | MEL Prior IO Rf-160/480 (Part D1 FDC) | MEL Prior IO Rf-160/480 (Part D2) | MEL 1L-160/480 (Part E) | MEL 1L-480/480 (Part E) | MEL Prior IO rf - 480/480 (Part E) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 2 | 1 | 0 | 2 | 3 | 1 | 3 | 3 | 0 | 1 | 0 | 21 |
| Not Hispanic or Latino | 4 | 4 | 4 | 8 | 7 | 5 | 5 | 6 | 7 | 4 | 7 | 8 | 6 | 13 | 11 | 10 | 20 | 4 | 10 | 14 | 28 | 10 | 21 | 42 | 52 | 33 | 33 | 83 | 33 | 35 | 41 | 568 |
| Unknown or Not Reported | 0 | 0 | 0 | 3 | 0 | 3 | 3 | 2 | 1 | 4 | 1 | 0 | 1 | 4 | 7 | 14 | 46 | 22 | 55 | 48 | 64 | 26 | 36 | 107 | 134 | 49 | 46 | 78 | 44 | 41 | 54 | 893 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Nov 2013 to primary completion in May 2024, 126 months.
Results were first posted in Jan 2026, 1 year 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Relatlimab